229 related articles for article (PubMed ID: 32503978)
1. MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies.
Swaminathan S; Hansen AS; Heftdal LD; Dhanasekaran R; Deutzmann A; Fernandez WDM; Liefwalker DF; Horton C; Mosley A; Liebersbach M; Maecker HT; Felsher DW
Nat Commun; 2020 Jun; 11(1):2860. PubMed ID: 32503978
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia.
Kumar A; Taghi Khani A; Duault C; Aramburo S; Sanchez Ortiz A; Lee SJ; Chan A; McDonald T; Huang M; Lacayo NJ; Sakamoto KM; Yu J; Hurtz C; Carroll M; Tasian SK; Ghoda L; Marcucci G; Gu Z; Rosen ST; Armenian S; Izraeli S; Chen CW; Caligiuri MA; Forman SJ; Maecker HT; Swaminathan S
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37217248
[TBL] [Abstract][Full Text] [Related]
3. STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity.
Meissl K; Simonović N; Amenitsch L; Witalisz-Siepracka A; Klein K; Lassnig C; Puga A; Vogl C; Poelzl A; Bosmann M; Dohnal A; Sexl V; Müller M; Strobl B
Front Immunol; 2020; 11():2189. PubMed ID: 33042133
[TBL] [Abstract][Full Text] [Related]
4. Association between c-Myc Expression with Clinicopathological Features in T And NK Cell Lymphomas.
Hasenan N; Mohd Isa SA; Hussain FA
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4011-4016. PubMed ID: 34967583
[TBL] [Abstract][Full Text] [Related]
5. The Inhibitory NKR-P1B:Clr-b Recognition Axis Facilitates Detection of Oncogenic Transformation and Cancer Immunosurveillance.
Tanaka M; Fine JH; Kirkham CL; Aguilar OA; Belcheva A; Martin A; Ketela T; Moffat J; Allan DSJ; Carlyle JR
Cancer Res; 2018 Jul; 78(13):3589-3603. PubMed ID: 29691253
[TBL] [Abstract][Full Text] [Related]
6. High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells.
Miyagi T; Gil MP; Wang X; Louten J; Chu WM; Biron CA
J Exp Med; 2007 Oct; 204(10):2383-96. PubMed ID: 17846149
[TBL] [Abstract][Full Text] [Related]
7. The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.
Cotta CV; Leventaki V; Atsaves V; Vidaki A; Schlette E; Jones D; Medeiros LJ; Rassidakis GZ
Cancer; 2008 Feb; 112(3):552-61. PubMed ID: 18085637
[TBL] [Abstract][Full Text] [Related]
8. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma.
Schlee M; Hölzel M; Bernard S; Mailhammer R; Schuhmacher M; Reschke J; Eick D; Marinkovic D; Wirth T; Rosenwald A; Staudt LM; Eilers M; Baran-Marszak F; Fagard R; Feuillard J; Laux G; Bornkamm GW
Int J Cancer; 2007 Apr; 120(7):1387-95. PubMed ID: 17211884
[TBL] [Abstract][Full Text] [Related]
9. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC.
Smith DP; Bath ML; Harris AW; Cory S
Oncogene; 2005 May; 24(22):3544-53. PubMed ID: 15688022
[TBL] [Abstract][Full Text] [Related]
10. CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
Al Sayed MF; Ruckstuhl CA; Hilmenyuk T; Claus C; Bourquin JP; Bornhauser BC; Radpour R; Riether C; Ochsenbein AF
Blood; 2017 Jul; 130(3):297-309. PubMed ID: 28495792
[TBL] [Abstract][Full Text] [Related]
11. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
12. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
[TBL] [Abstract][Full Text] [Related]
13. Expression of cyclin-dependent kinase 6 (cdk6) and frequent loss of CD44 in nasal-nasopharyngeal NK/T-cell lymphomas: comparison with CD56-negative peripheral T-cell lymphomas.
Lien HC; Lin CW; Huang PH; Chang ML; Hsu SM
Lab Invest; 2000 Jun; 80(6):893-900. PubMed ID: 10879740
[TBL] [Abstract][Full Text] [Related]
14. Establishment of bioluminescent imaging model using murine T cell lymphoma susceptive to NK cell-dependent immune-surveillance.
Fujiwara T; Miyazato K; Takahashi K; Hayakawa Y
J Immunol Methods; 2021 Apr; 491():112993. PubMed ID: 33609531
[TBL] [Abstract][Full Text] [Related]
15. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
16. Premalignant PTEN-deficient thymocytes activate microRNAs miR-146a and miR-146b as a cellular defense against malignant transformation.
Burger ML; Xue L; Sun Y; Kang C; Winoto A
Blood; 2014 Jun; 123(26):4089-100. PubMed ID: 24735967
[TBL] [Abstract][Full Text] [Related]
17. Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.
Harrington CT; Sotillo E; Robert A; Hayer KE; Bogusz AM; Psathas J; Yu D; Taylor D; Dang CV; Klein PS; Hogarty MD; Geoerger B; El-Deiry WS; Wiels J; Thomas-Tikhonenko A
Leukemia; 2019 Oct; 33(10):2429-2441. PubMed ID: 30914792
[TBL] [Abstract][Full Text] [Related]
18. Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma.
Belting L; Hömberg N; Przewoznik M; Brenner C; Riedel T; Flatley A; Polić B; Busch DH; Röcken M; Mocikat R
Eur J Immunol; 2015 Sep; 45(9):2593-601. PubMed ID: 26151313
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-β directly induces p53-up-regulated modulator of apoptosis (PUMA) during the rapid induction of apoptosis in myc-driven B-cell lymphomas.
Spender LC; Carter MJ; O'Brien DI; Clark LJ; Yu J; Michalak EM; Happo L; Cragg MS; Inman GJ
J Biol Chem; 2013 Feb; 288(7):5198-209. PubMed ID: 23243310
[TBL] [Abstract][Full Text] [Related]
20. Myc suppression of Nfkb2 accelerates lymphomagenesis.
Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
